RU2016147020A - Водно-спиртовая система для лечения ногтей - Google Patents
Водно-спиртовая система для лечения ногтей Download PDFInfo
- Publication number
- RU2016147020A RU2016147020A RU2016147020A RU2016147020A RU2016147020A RU 2016147020 A RU2016147020 A RU 2016147020A RU 2016147020 A RU2016147020 A RU 2016147020A RU 2016147020 A RU2016147020 A RU 2016147020A RU 2016147020 A RU2016147020 A RU 2016147020A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- weight
- mixtures
- group
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 6
- 229940088623 biologically active substance Drugs 0.000 claims 6
- 229920001992 poloxamer 407 Polymers 0.000 claims 6
- 229940044476 poloxamer 407 Drugs 0.000 claims 6
- 229920000858 Cyclodextrin Polymers 0.000 claims 5
- 239000003961 penetration enhancing agent Substances 0.000 claims 5
- 229940097362 cyclodextrins Drugs 0.000 claims 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 229960004399 carbocisteine Drugs 0.000 claims 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims 1
- 229960004703 clobetasol propionate Drugs 0.000 claims 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims 1
- 229960002722 terbinafine Drugs 0.000 claims 1
- -1 their derivatives Polymers 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Claims (15)
1. Фармацевтическая композиция, содержащая (i) полоксамер 407, (ii) по меньшей мере один усилитель проникновения, (iii) по меньшей мере один солюбилизирующий агент, выбранный из группы, состоящей из циклодекстринов, гидрофильных полимеров и их смесей, (iv) по меньшей мере одно биологически активное вещество и (v) носитель, содержащий воду и спирт C1-С3, или их смеси.
2. Фармацевтическая композиция по п. 1, отличающаяся тем, что соотношение вода: спирт C1-С3 находится в диапазоне от 20:1 до 1:20.
3. Фармацевтическая композиция по п. 2, отличающаяся тем, что соотношение вода: спирт C1-С3 находится в диапазоне от 4:1 до 1:4.
4. Фармацевтическая композиция по любому из предыдущих пунктов, отличающаяся тем, что указанный носитель состоит из смеси воды и спирта C1-С3.
5. Фармацевтическая композиция по любому из предыдущих пунктов, содержащая циклодекстрин вплоть до 20% вес. по отношению к общей массе фармацевтической композиции.
6. Фармацевтическая композиция по любому из предыдущих пунктов, содержащая полоксамер 407 в диапазоне от 1% до 40% вес. по отношению к общей массе фармацевтической композиции полоксамера 407.
7. Фармацевтическая композиция по любому из предыдущих пунктов, отличающаяся тем, что указанный усилитель проникновения выбирают из группы, состоящей из N-ацетилцистеина в количестве от 0,01% до 15% вес., додецилсульфата натрия в количестве от 0,01% до 10% вес., PEG в количестве от 2% до 7% вес. и комбинации PEG в количестве от 2% до 7% вес. с карбоцистеином в количестве от 0,01% до 0,2% вес.
8. Фармацевтическая композиция по п. 1, содержащая (i) от 5% до 25% вес. полоксамера 407, (ii) от 0,01% до 12% вес. по меньшей мере одного усилителя проникновения, (iii) от 5% до 25% вес. по меньшей мере одного солюбилизирующего агента, выбранного из группы, состоящей из циклодекстринов, их производных, гидрофильных полимеров и их смесей, (iv) по меньшей мере одно биологически активное вещество до насыщения и (v) носитель, содержащий воду и спирт C1-С3, или их смеси в количестве, необходимом для доведения до 100% вес.
9. Фармацевтическая композиция по любому из предыдущих пунктов, отличающаяся тем, что указанное биологически активное вещество выбирают из группы, состоящей из противогрибковых препаратов, стероидных противовоспалительных препаратов, кортикоидов, ретиноидов, витамина D и их производных, иммунодепрессантов, противовирусных препаратов, антибиотиков и их смесей.
10. Фармацевтическая композиция по п. 9, отличающаяся тем, что указанное биологически активное вещество выбирают из группы, состоящей из клобетазола пропионата, циклопирокса и тербинафина.
11. Фармацевтическая композиция по любому из пп. 1-10 для применения в качестве лекарственного препарата.
12. Фармацевтическая композиция по любому из пп. 1-10 для применения при лечении и предупреждении патологических состояний ногтей.
13. Фармацевтическая композиция по п. 12 для применения при лечении патологического состояния, выбранного из группы, состоящей из грибковых инфекций, псориаза, красного плоского лишая, воспаления, атопического дерматита, экземы, а также вирусных и бактериальных инфекций.
14. Способ приготовления фармацевтической композиции, который включает смешивание (i) полоксамера 407, (ii) по меньшей мере одного усилителя проникновения, (iii) по меньшей мере одного солюбилизирующего агента, выбранного из группы, состоящей из циклодекстринов, гидрофильных полимеров и их смесей, (iv) по меньшей мере одного биологически активного вещества и (v) носителя, содержащего воду и спирт C1-С3, или их смесей.
15. Набор, содержащий фармацевтическую композицию, которая содержит (i) полоксамер 407, (ii) по меньшей мере один усилитель проникновения, (iii) по меньшей мере один солюбилизирующий агент, выбранный из группы, состоящей из циклодекстринов, гидрофильных полимеров и их смесей, (iv) по меньшей мере одно биологически активное вещество и (v) носитель, содержащий воду и спирт C1-С3, или их смеси; и инструкции по нанесению указанной фармацевтической композиции на ноготь.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382215.3 | 2014-06-04 | ||
| EP14382215.3A EP2952208A1 (en) | 2014-06-04 | 2014-06-04 | Hydroalcoholic system for nail treatment |
| PCT/EP2015/062413 WO2015185647A1 (en) | 2014-06-04 | 2015-06-03 | Hydroalcoholic system for nail treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016147020A true RU2016147020A (ru) | 2018-05-30 |
| RU2016147020A3 RU2016147020A3 (ru) | 2018-12-26 |
| RU2730010C2 RU2730010C2 (ru) | 2020-08-14 |
Family
ID=50942639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016147020A RU2730010C2 (ru) | 2014-06-04 | 2015-06-03 | Водно-спиртовая система для лечения ногтей |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20170224669A1 (ru) |
| EP (2) | EP2952208A1 (ru) |
| JP (1) | JP6742920B2 (ru) |
| KR (1) | KR102394176B1 (ru) |
| CN (1) | CN106456781B (ru) |
| AU (1) | AU2015270537B2 (ru) |
| BR (1) | BR112016028412B1 (ru) |
| CA (1) | CA2950478C (ru) |
| ES (1) | ES2831973T3 (ru) |
| HU (1) | HUE051352T2 (ru) |
| LT (1) | LT3151863T (ru) |
| MX (1) | MX375244B (ru) |
| PL (1) | PL3151863T3 (ru) |
| PT (1) | PT3151863T (ru) |
| RU (1) | RU2730010C2 (ru) |
| SI (1) | SI3151863T1 (ru) |
| WO (1) | WO2015185647A1 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024507612A (ja) * | 2021-01-15 | 2024-02-21 | エルジー ハウスホールド アンド ヘルスケア リミテッド | 角質剥離または皮膚状態改善用組成物 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0039132B1 (en) | 1980-04-29 | 1984-02-01 | LUCAS INDUSTRIES public limited company | Brake master cylinder |
| DE3544983A1 (de) | 1985-12-19 | 1987-06-25 | Hoechst Ag | Antimykotisch wirksamer nagellack |
| DE3720147A1 (de) | 1987-06-16 | 1988-12-29 | Hoechst Ag | Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung |
| CA2008775C (en) | 1989-02-24 | 1998-12-22 | Alberto Ferro | Nail lacquer |
| DE4212105A1 (de) | 1992-04-10 | 1993-10-14 | Roehm Pharma Gmbh | Nagellack zur Behandlung von Onychomykosen |
| US5464610A (en) | 1992-10-15 | 1995-11-07 | Schering-Plough Healthcare Products, Inc. | Method for treating onychomycosis |
| FR2705563B1 (fr) | 1993-05-26 | 1995-07-07 | Oreal | Vernis à ongles aqueux, incolore ou coloré, contenant un polymère filmogène à l'état dispersé et un composé perfluoroalkyle hydrosoluble. |
| US5391367A (en) | 1993-07-28 | 1995-02-21 | Pfizer Inc. | Antifungal nail solution |
| FR2711059B1 (fr) | 1993-10-15 | 1996-02-02 | Oreal | Composition cosmétique sous forme de vernis à ongles aqueux, coloré ou incolore, contenant en tant que substance filmogène des particules de polyester-polyuréthanne anionique à l'état dispersé. |
| JPH07223942A (ja) * | 1994-02-03 | 1995-08-22 | Ildong Pharm Co Ltd | プロピオン酸系非ステロイド性薬物を有効成分として含有する新規消炎鎮痛外用ゲル製剤 |
| US5487776A (en) | 1994-03-17 | 1996-01-30 | Nimni; Marcel | Anti-fungal nail lacquer and method therefor |
| US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
| US5696105A (en) | 1996-03-14 | 1997-12-09 | Hackler; Walter A. | Antifungal nail composition |
| KR100220403B1 (ko) * | 1997-03-25 | 1999-09-15 | 박성원 | 각질 투과 증가제를 기제성분으로 함유하는 항진균성 손.발톱 와니스 |
| CA2278328C (en) | 1998-02-09 | 2008-07-22 | Macrochem Corporation | Antifungal nail lacquer and method using same |
| FR2775593B1 (fr) | 1998-03-09 | 2002-06-14 | Oreal | Composition filmogene comprenant un polyurethane en dispersion aqueuse et un agent plastifiant |
| US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
| US6495124B1 (en) | 2000-02-14 | 2002-12-17 | Macrochem Corporation | Antifungal nail lacquer and method using same |
| DE10035991A1 (de) | 2000-07-24 | 2002-02-14 | Polichem Sa | Nagellackzusammensetzung |
| US20030049320A1 (en) * | 2000-12-18 | 2003-03-13 | Wockhardt Limited | Novel in-situ forming controlled release microcarrier delivery system |
| US6881726B2 (en) * | 2001-12-24 | 2005-04-19 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
| HRP20050918A2 (en) * | 2003-03-21 | 2006-12-31 | Nexmed Holdings | Antifungal nail coat and method of use |
| EP1491202A1 (en) * | 2003-06-23 | 2004-12-29 | Polichem S.A. | Nail restructuring compositions for topical application |
| RU2238722C1 (ru) * | 2003-06-25 | 2004-10-27 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция с обезболивающим и противовоспалительным действием |
| US20050238672A1 (en) * | 2004-04-27 | 2005-10-27 | Nimni Marcel E | Antifungal drug delivery |
| CN101351227A (zh) | 2005-12-28 | 2009-01-21 | 帝国制药株式会社 | 指甲用医药组合物 |
| GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
| GB0720716D0 (en) * | 2007-10-23 | 2007-12-05 | York Pharma Plc | Novel formulation |
| US20090175810A1 (en) * | 2008-01-03 | 2009-07-09 | Gareth Winckle | Compositions and methods for treating diseases of the nail |
| US20090175945A1 (en) | 2008-01-08 | 2009-07-09 | Jie Zhang | Systems, Methods, and Formulations for Topically Treating Nail Fungal Infections and Nail Psoriasis |
| AU2009205314A1 (en) * | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
| EP2544659A2 (en) * | 2009-12-23 | 2013-01-16 | Nuvo Research Inc. | Highly permeating terbinafine formulation for treating onychomycosis |
| ES2369101B2 (es) | 2010-05-07 | 2012-08-02 | Universidade De Santiago De Compostela | Sistema farmacéutico acuoso para la administración de fármacos en las uñas. |
| JP2012017318A (ja) * | 2010-06-07 | 2012-01-26 | Nikko Chemical Co Ltd | 液晶及びそれを含有する皮膚外用剤 |
-
2014
- 2014-06-04 EP EP14382215.3A patent/EP2952208A1/en not_active Withdrawn
-
2015
- 2015-06-03 US US15/315,314 patent/US20170224669A1/en not_active Abandoned
- 2015-06-03 LT LTEP15725664.5T patent/LT3151863T/lt unknown
- 2015-06-03 BR BR112016028412-7A patent/BR112016028412B1/pt active IP Right Grant
- 2015-06-03 RU RU2016147020A patent/RU2730010C2/ru active
- 2015-06-03 MX MX2016016079A patent/MX375244B/es active IP Right Grant
- 2015-06-03 EP EP15725664.5A patent/EP3151863B1/en active Active
- 2015-06-03 AU AU2015270537A patent/AU2015270537B2/en active Active
- 2015-06-03 WO PCT/EP2015/062413 patent/WO2015185647A1/en not_active Ceased
- 2015-06-03 KR KR1020167033922A patent/KR102394176B1/ko active Active
- 2015-06-03 PL PL15725664T patent/PL3151863T3/pl unknown
- 2015-06-03 CA CA2950478A patent/CA2950478C/en active Active
- 2015-06-03 JP JP2016570778A patent/JP6742920B2/ja active Active
- 2015-06-03 PT PT157256645T patent/PT3151863T/pt unknown
- 2015-06-03 CN CN201580030022.5A patent/CN106456781B/zh active Active
- 2015-06-03 ES ES15725664T patent/ES2831973T3/es active Active
- 2015-06-03 HU HUE15725664A patent/HUE051352T2/hu unknown
- 2015-06-03 SI SI201531410T patent/SI3151863T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20170224669A1 (en) | 2017-08-10 |
| EP2952208A1 (en) | 2015-12-09 |
| CA2950478C (en) | 2022-04-12 |
| PL3151863T3 (pl) | 2021-03-08 |
| CN106456781A (zh) | 2017-02-22 |
| BR112016028412A2 (pt) | 2017-08-22 |
| HUE051352T2 (hu) | 2021-03-01 |
| BR112016028412B1 (pt) | 2023-05-02 |
| EP3151863B1 (en) | 2020-08-12 |
| AU2015270537A1 (en) | 2016-12-15 |
| LT3151863T (lt) | 2021-08-10 |
| KR102394176B1 (ko) | 2022-05-03 |
| MX375244B (es) | 2025-03-06 |
| CA2950478A1 (en) | 2015-12-10 |
| PT3151863T (pt) | 2020-11-19 |
| SI3151863T1 (sl) | 2021-03-31 |
| RU2730010C2 (ru) | 2020-08-14 |
| KR20170008763A (ko) | 2017-01-24 |
| ES2831973T3 (es) | 2021-06-09 |
| CN106456781B (zh) | 2020-07-10 |
| EP3151863A1 (en) | 2017-04-12 |
| RU2016147020A3 (ru) | 2018-12-26 |
| WO2015185647A1 (en) | 2015-12-10 |
| MX2016016079A (es) | 2017-07-28 |
| AU2015270537B2 (en) | 2019-12-05 |
| JP6742920B2 (ja) | 2020-08-19 |
| JP2017523135A (ja) | 2017-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210342T1 (hr) | Pripravci glikopeptida | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| JP2017526738A5 (ru) | ||
| MX2020005942A (es) | Delgada pelicula oral con alta carga de agente activo. | |
| ES2543957T3 (es) | Nueva composición farmacéutica para el tratamiento de infecciones fúngicas | |
| MX2019006221A (es) | Preparacion de complejos solidos de ciclodextrina para suministro de ingredientes farmaceuticos activos oftalmicos. | |
| BR112017008660A2 (pt) | formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf | |
| CL2009000902A1 (es) | Composicion que comprende posaconazol disuelto o disperso molecularmente en un polimero derivado de hidroxipropilcelulosa; formulacion farmaceutica que comprende a la composion; un proceso para preparar a la composicion mediante fusioextrusion; y su uso para tratar una infeccion micotica. | |
| MX393613B (es) | Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas. | |
| BR112014030820A2 (pt) | formulação de anticorpos | |
| JP2017533218A5 (ru) | ||
| MX2011012143A (es) | Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas. | |
| HK1251481A1 (zh) | 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| BR112019003136A2 (pt) | forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo | |
| MX2023006235A (es) | Composiciones para administracion de farmacos y metodos de uso de las mismas. | |
| EA201891649A1 (ru) | C-3 и c-17 модифицированные тритерпеноиды в качестве ингибиторов вич-1 | |
| EP4477265A3 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| US20160331764A1 (en) | Composition comprising xylitol and cholecalciferol for topical treatment of skin and mucous membranes | |
| RU2016147020A (ru) | Водно-спиртовая система для лечения ногтей | |
| WO2013182998A4 (en) | Cosmetic and / or pharmaceutical composition for the treatment of skin inflammation and related syndromes | |
| BR112017009850A2 (pt) | composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto | |
| MX389461B (es) | Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos | |
| MX2021000769A (es) | Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma. | |
| RU2018119510A (ru) | Композиции изотретиноина и их применение и способы | |
| CL2022003426A1 (es) | Composición farmacéutica acuosa de levilimab y su uso |